(many cases presentation)
Every Cancer Patient should have right to refer himself/ herself to Oncology speciality, and waiting for primary care physician referring can cause protract cancer care, I found that can be avoided.
Let us see table ‘Outcome affects by cancer patient’s choice’
Metastatic Breast Cancer
(1) Patient A
(2) Patient B
(3) Phase III trial of nab-paclitaxel compared with Docetaxel as first line Chemotherapy in patient with metastatic breast cancer final analysis overall survival (by William J. Gradisbar et. al Published on Clinical Breast cancer Oct. 2012, P313-321)
Nearly 9 years
More than 4 years
Best result in Nabpaclitaxel arm less than 3 years
Yes, on clinical trial
NONE (on Dr. Fan’s treatment)
Both Patient A and Patient B were initial diagnosed breast cancer in 1995.
Patient A then diagnosed Bone metastasis in 2003. She chosen mine ‘personalized medicine’ treatment for nearly 8 years , No toxicities during the treatment . Now, nearly 9 years, patient A is treatment free, lives fully normal life.
Patient B, Diagnosed Bone metastasis in early 2001. She then chosen alternated clinical trial and my personalized treatment, during her clinical trial phase, she suffered treatment toxicity along with cancer progression. She then seeking my treatment, she was getting better, she then changed back to chemotherapy, died in late Autumn 2005.
The third group, on the table showed the clinical phase II trial, the best result among the 4 arms trial is Nab-paclitaxel. median overall survival 33.8 months (less than three years) with many treatment related toxicity.
- Metastatic Breast Cancer
- Therapy Comparison
- Case 1: Esophageal Cancer
- Case 2: Nasopharyngeal Cancer
- Case 3: Nasopharyngeal Cancer
- Case 4: Breast Cancer w/ Liver & Bone Mets.
- Case 5: Breast Cancer w/ Bone Mets.
- Case 6: Extranodal NK’T-cell Lymphoma
- Case 7: Breast Cancer Survival w/ Thyroid Tumors
- Case 8: GBM- Glioblastoma-multiform
- Case 9: Recurrent Adenocystic Carcinoma